Retatrutide Investigated for Weight Loss and Knee Osteoarthritis Improvement

Obesity and overweight are significant risk factors for the development and progression of osteoarthritis (OA), particularly in weight-bearing joints like the knee. The excess mechanical load and systemic inflammation associated with higher body weight exacerbate joint damage and pain, leading to reduced mobility and quality of life. While weight loss is a primary recommendation for managing knee OA in individuals with obesity, there is a critical need for therapies that can effectively address both conditions simultaneously. This Phase 3 study aims to evaluate the safety and efficacy of Retatrutide in improving both body weight and knee osteoarthritis symptoms in a single treatment regimen.

This Phase 3 trial is designed to evaluate if Retatrutide leads to significant improvements in both body weight and knee osteoarthritis symptoms. Based on prior research on Retatrutide's triple agonist mechanism (targeting GLP-1, GIP, and glucagon receptors), it is anticipated that participants receiving Retatrutide will achieve a substantial mean body weight reduction, potentially exceeding 20% from baseline, compared to a minimal change in the placebo group (<1%). This significant weight loss is expected to translate into clinically meaningful improvements in osteoarthritis outcomes. The study aims to demonstrate a significant reduction in knee pain scores, with an anticipated 35% decrease in the Retatrutide group versus 10% in the placebo group (p<0.001), alongside a 2.5-fold improvement in physical function. Furthermore, secondary endpoints are expected to show improvements in joint stiffness and quality of life, with Retatrutide potentially reducing stiffness by 40% compared to 15% with placebo. The safety profile will also be rigorously assessed, with anticipated rates of gastrointestinal side effects consistent with other incretin-based therapies, generally mild to moderate.